{
  "retracted": false,
  "timestamp": 1475280000000,
  "updates": [
    {
      "timestamp": 1495734707645,
      "identifier": {
        "doi": "10.1016/j.ygyno.2016.07.097"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.ygyno.2016.05.015"
  },
  "journal": "Gynecologic Oncology",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center” [Gynecol. Oncol. 142 (2016) 13–18]"
}
